Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Rituximab plus Lenalidomide in MALT Lymphoma
2011-005818-10Phase 2Completed
- Sponsor
- AGMT
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and lenalidomide in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by AGMT. Primary endpoint: Objective response rate. Started Feb 2012; status: completed.
02
Drugs
rituximablenalidomide
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2011-005818-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005818-10.